Sinovac Biotech Stock Price, News & Analysis (NASDAQ:SVA)

$8.04 -0.03 (-0.37 %)
(As of 01/18/2018 04:00 PM ET)
Previous Close$8.07
Today's Range$8.01 - $8.07
52-Week Range$4.60 - $8.11
Volume32,200 shs
Average Volume89,036 shs
Market Capitalization$460.08 million
P/E Ratio25.13
Dividend YieldN/A
Beta0.13

About Sinovac Biotech (NASDAQ:SVA)

Sinovac Biotech logoSinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Receive SVA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorBiopharmaceuticals
SymbolNASDAQ:SVA
CUSIPN/A
Phone+86-10-82890088

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio25.125
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$72.43 million
Price / Sales6.33
Cash Flow$0.05 per share
Price / Cash149.84
Book Value$2.28 per share
Price / Book3.53

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees724
Outstanding Shares57,020,000

Sinovac Biotech (NASDAQ:SVA) Frequently Asked Questions

What is Sinovac Biotech's stock symbol?

Sinovac Biotech trades on the NASDAQ under the ticker symbol "SVA."

How were Sinovac Biotech's earnings last quarter?

Sinovac Biotech Ltd. (NASDAQ:SVA) issued its earnings results on Wednesday, November, 22nd. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter. View Sinovac Biotech's Earnings History.

Who are some of Sinovac Biotech's key competitors?

Who are Sinovac Biotech's key executives?

Sinovac Biotech's management team includes the folowing people:

  • Weidong Yin, Chairman of the Board, President, Chief Executive Officer, Secretary (Age 48)
  • Nan Wang, Chief Financial Officer (Age 46)
  • Ming Xia, Vice President - Sales and Marketing of Sinovac Beijing (Age 38)
  • Simon J. Anderson, Independent Director (Age 53)
  • Jue Lee, Independent Director (Age 47)
  • Yuk Lam Lo, Independent Director (Age 68)
  • Meng Mei, Independent Director (Age 58)

How do I buy Sinovac Biotech stock?

Shares of Sinovac Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sinovac Biotech's stock price today?

One share of Sinovac Biotech stock can currently be purchased for approximately $8.04.

How big of a company is Sinovac Biotech?

Sinovac Biotech has a market capitalization of $460.08 million and generates $72.43 million in revenue each year. The biopharmaceutical company earns $-590,000.00 in net income (profit) each year or $0.32 on an earnings per share basis. Sinovac Biotech employs 724 workers across the globe.

How can I contact Sinovac Biotech?

Sinovac Biotech's mailing address is 39 Shangdi Xi Road, Haidian District, BEIJING, BEJ 100085, China. The biopharmaceutical company can be reached via phone at +86-10-82890088 or via email at [email protected]


MarketBeat Community Rating for Sinovac Biotech (SVA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  186
MarketBeat's community ratings are surveys of what our community members think about Sinovac Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sinovac Biotech (NASDAQ:SVA) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Sinovac Biotech (NASDAQ:SVA) Earnings History and Estimates Chart

Earnings by Quarter for Sinovac Biotech (NASDAQ:SVA)

Sinovac Biotech (NASDAQ SVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/22/2017Q4 2016$0.08ViewN/AView Earnings Details
11/28/2016Q316$0.05$0.06$16.76 million$28.74 millionViewN/AView Earnings Details
8/23/2016Q2($0.15)$18.49 billion$1.38 billionViewListenView Earnings Details
5/26/2016Q116($0.01)$10.95 millionViewN/AView Earnings Details
4/5/2016Q415$0.01$22.95 millionViewN/AView Earnings Details
11/11/2015Q315($0.02)($0.03)$27.10 million$16.80 millionViewListenView Earnings Details
8/12/2015Q215($0.01)$0.04$15.70 million$18.50 millionViewListenView Earnings Details
5/15/2015Q115$0.02($0.04)$12.70 million$9.27 millionViewN/AView Earnings Details
4/20/2015Q414$0.01$0.02$14.10 million$22.90 millionViewN/AView Earnings Details
8/14/2014Q214$0.01($0.04)$17.20 million$12.10 millionViewN/AView Earnings Details
3/19/2014Q4 13($0.01)$0.10$18.75 million$22.90 millionViewN/AView Earnings Details
11/12/2013Q3$0.04ViewListenView Earnings Details
8/13/2013Q2 2013$0.02ViewN/AView Earnings Details
5/28/2013Q1 2013($0.04)ViewN/AView Earnings Details
4/18/2013Q4 2012($0.08)ViewN/AView Earnings Details
11/15/2012Q312($0.03)($0.06)$12.35 million$14.30 millionViewN/AView Earnings Details
8/15/2012Q2 2012($0.02)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.13)($0.10)ViewN/AView Earnings Details
3/29/2012Q4 2011$0.05ViewN/AView Earnings Details
11/14/2011Q3 2011$0.02($0.04)ViewN/AView Earnings Details
8/12/2011Q2 2011($0.01)$0.02ViewN/AView Earnings Details
5/13/2011Q1 2011($0.05)ViewN/AView Earnings Details
3/31/2011Q4 2010$0.02($0.17)ViewN/AView Earnings Details
11/15/2010Q3 2010$0.05($0.01)ViewN/AView Earnings Details
8/16/2010Q2 2010$0.01$0.02ViewN/AView Earnings Details
5/13/2010Q1 2010$0.02($0.01)ViewN/AView Earnings Details
4/6/2010Q4 2009$0.21ViewN/AView Earnings Details
11/15/2009Q3 2009$0.07$0.12ViewN/AView Earnings Details
8/19/2009Q2 2009$0.14ViewN/AView Earnings Details
4/9/2009Q4 2008$0.04$0.06ViewN/AView Earnings Details
11/18/2008Q3 2008$0.03$0.02ViewN/AView Earnings Details
8/13/2008Q2 2008$0.08$0.08ViewN/AView Earnings Details
5/16/2008Q1 2008$0.04ViewN/AView Earnings Details
3/31/2008Q4 2007$0.05$0.05ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Sinovac Biotech (NASDAQ:SVA) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Sinovac Biotech (NASDAQ:SVA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Sinovac Biotech (NASDAQ SVA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 31.80%
Insider Trades by Quarter for Sinovac Biotech (NASDAQ:SVA)
Institutional Ownership by Quarter for Sinovac Biotech (NASDAQ:SVA)

Sinovac Biotech (NASDAQ SVA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/20/2017Scott LangilleInsiderBuy100,000$0.27$27,000.00
4/19/2017Scott LangilleInsiderBuy50,000$0.27$13,500.00
4/18/2017Scott LangilleInsiderBuy25,000$0.26$6,500.00
4/17/2017James Todd ParsonsDirectorSell272$0.25$68.00
4/17/2017Scott LangilleInsiderBuy24,500$0.26$6,370.00
4/13/2017James Todd ParsonsDirectorSell166,500$0.25$41,625.00
4/11/2017James Todd ParsonsDirectorSell33,500$0.25$8,375.00
12/30/2015Jeffrey BachaDirectorSell10,000$0.30$2,950.00
12/29/2015Jeffrey BachaDirectorSell21,500$0.30$6,342.50
(Data available from 1/1/2013 forward)

Headlines

Sinovac Biotech (NASDAQ SVA) News Headlines

Source:
DateHeadline
Analyzing Catalyst Biosciences (CBIO) & Sinovac Biotech (SVA)Analyzing Catalyst Biosciences (CBIO) & Sinovac Biotech (SVA)
www.americanbankingnews.com - January 12 at 7:48 AM
Reviewing Myovant Sciences (MYOV) and Sinovac Biotech (SVA)Reviewing Myovant Sciences (MYOV) and Sinovac Biotech (SVA)
www.americanbankingnews.com - January 6 at 11:36 PM
What You Must Know About Sinovac Biotech Ltd’s (NASDAQ:SVA) RisksWhat You Must Know About Sinovac Biotech Ltd’s (NASDAQ:SVA) Risks
finance.yahoo.com - January 5 at 3:23 PM
Sinovac Schedules 2017 Annual Meeting of ShareholdersSinovac Schedules 2017 Annual Meeting of Shareholders
finance.yahoo.com - December 29 at 8:52 AM
Should You Be Tempted To Buy Sinovac Biotech Ltd (NASDAQ:SVA) Because Of Its PE Ratio?Should You Be Tempted To Buy Sinovac Biotech Ltd (NASDAQ:SVA) Because Of Its PE Ratio?
finance.yahoo.com - December 28 at 1:49 PM
Sinovac Biotech (SVA) Cut to Hold at BidaskClubSinovac Biotech (SVA) Cut to Hold at BidaskClub
www.americanbankingnews.com - December 27 at 9:53 AM
Anika Therapeutics (ANIK) vs. Sinovac Biotech (SVA) Critical ReviewAnika Therapeutics (ANIK) vs. Sinovac Biotech (SVA) Critical Review
www.americanbankingnews.com - December 24 at 3:30 PM
Sinovac Biotech (SVA) Announces Positive Decision on its Hepatitis A Vaccine from World Health OrganizationSinovac Biotech (SVA) Announces Positive Decision on its Hepatitis A Vaccine from World Health Organization
www.streetinsider.com - December 22 at 3:39 PM
Sinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine from World Health OrganizationSinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine from World Health Organization
finance.yahoo.com - December 22 at 3:39 PM
Sinovac Biotech (SVA) Downgraded by BidaskClub to BuySinovac Biotech (SVA) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - December 7 at 10:32 PM
Critical Analysis: Chiasma (CHMA) and Sinovac Biotech (SVA)Critical Analysis: Chiasma (CHMA) and Sinovac Biotech (SVA)
www.americanbankingnews.com - December 6 at 1:28 AM
Sinovac Biotech Now In Compliance With All Listing Standards - Quick FactsSinovac Biotech Now In Compliance With All Listing Standards - Quick Facts
www.rttnews.com - December 1 at 7:51 AM
Sinovac Biotech Cures Nasdaq Filing DeficiencySinovac Biotech Cures Nasdaq Filing Deficiency
finance.yahoo.com - December 1 at 7:51 AM
Sinovac Reports Unaudited First Half of 2017 Financial ResultsSinovac Reports Unaudited First Half of 2017 Financial Results
finance.yahoo.com - December 1 at 7:51 AM
Sinovac: Nasdaq Panel Extends Stay Of Suspension In Trading - Quick FactsSinovac: Nasdaq Panel Extends Stay Of Suspension In Trading - Quick Facts
www.nasdaq.com - November 30 at 7:23 AM
Sinovac Biotech Announces Update on Nasdaq MattersSinovac Biotech Announces Update on Nasdaq Matters
finance.yahoo.com - November 30 at 7:23 AM
Sinovac posts 4Q profitSinovac posts 4Q profit
finance.yahoo.com - November 23 at 3:25 PM
Sinovac Files 2016 Annual Report on Form 20-F and Reports Unaudited Fourth Quarter 2016 Financial ResultsSinovac Files 2016 Annual Report on Form 20-F and Reports Unaudited Fourth Quarter 2016 Financial Results
finance.yahoo.com - November 23 at 3:25 PM
Contrasting BioMarin Pharmaceutical (BMRN) and Sinovac Biotech (SVA)Contrasting BioMarin Pharmaceutical (BMRN) and Sinovac Biotech (SVA)
www.americanbankingnews.com - November 19 at 3:28 PM
Is Sinovac Biotech Ltd’s (SVA) Balance Sheet Strong Enough To Weather A Storm?Is Sinovac Biotech Ltd’s (SVA) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 11 at 2:13 PM
Sinovac Biotech Announces Request Hearing before Nasdaq Hearings PanelSinovac Biotech Announces Request Hearing before Nasdaq Hearings Panel
finance.yahoo.com - November 9 at 2:11 PM
Reviewing Sinovac Biotech (SVA) and The CompetitionReviewing Sinovac Biotech (SVA) and The Competition
www.americanbankingnews.com - November 7 at 2:06 PM
Sinovac Biotech, Ltd. (SVA) Lifted to Buy at BidaskClubSinovac Biotech, Ltd. (SVA) Lifted to Buy at BidaskClub
www.americanbankingnews.com - November 5 at 10:46 PM
Comparing Sinovac Biotech (SVA) and Its CompetitorsComparing Sinovac Biotech (SVA) and Its Competitors
www.americanbankingnews.com - November 5 at 9:24 AM
Sinovac Biotech Announces Receipt of Delisting Determination Letter from NasdaqSinovac Biotech Announces Receipt of Delisting Determination Letter from Nasdaq
finance.yahoo.com - November 5 at 5:25 AM
Sinovac Biotech (SVA) & Its Rivals Critical AnalysisSinovac Biotech (SVA) & Its Rivals Critical Analysis
www.americanbankingnews.com - November 3 at 11:20 PM
Contrasting Sinovac Biotech (SVA) & Its PeersContrasting Sinovac Biotech (SVA) & Its Peers
www.americanbankingnews.com - November 3 at 1:08 PM
Analyzing Sinovac Biotech (SVA) & Syndax Pharmaceuticals (SNDX)Analyzing Sinovac Biotech (SVA) & Syndax Pharmaceuticals (SNDX)
www.americanbankingnews.com - October 22 at 6:24 AM
Financial Analysis: Opiant Pharmaceuticals (OPNT) and Sinovac Biotech (SVA)Financial Analysis: Opiant Pharmaceuticals (OPNT) and Sinovac Biotech (SVA)
www.americanbankingnews.com - October 16 at 6:28 PM
Financial Survey: Sinovac Biotech (SVA) & The CompetitionFinancial Survey: Sinovac Biotech (SVA) & The Competition
www.americanbankingnews.com - October 14 at 4:14 AM
Sinovac Completed its 23-Valent Pneumococcal Polysaccharide Vaccine Phase III Clinical Trial and Filed the New Drug Application to CFDASinovac Completed its 23-Valent Pneumococcal Polysaccharide Vaccine Phase III Clinical Trial and Filed the New Drug Application to CFDA
finance.yahoo.com - October 12 at 3:45 PM
Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for Varicella Vaccine Candidate Against ChickenpoxSinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for Varicella Vaccine Candidate Against Chickenpox
finance.yahoo.com - October 3 at 1:09 PM
Sinobioway Consortium Updates On Offer To Buy Sinovac BiotechSinobioway Consortium Updates On Offer To Buy Sinovac Biotech
www.nasdaq.com - September 30 at 8:01 PM
Sinovacs chickenpox vaccine 87.1% effective in late-stage study; shares up 7% premarketSinovac's chickenpox vaccine 87.1% effective in late-stage study; shares up 7% premarket
seekingalpha.com - September 27 at 5:43 PM
Sinovac Biotech (SVA) versus Syndax Pharmaceuticals (SNDX) Financial AnalysisSinovac Biotech (SVA) versus Syndax Pharmaceuticals (SNDX) Financial Analysis
www.americanbankingnews.com - September 23 at 2:44 PM
Should You Be Concerned About Sinovac Biotech Ltd’s (SVA) Risks?Should You Be Concerned About Sinovac Biotech Ltd’s (SVA) Risks?
finance.yahoo.com - September 12 at 10:27 AM
Sinovac Biotech Ltd. breached its 50 day moving average in a Bearish Manner : SVA-US : September 8, 2017Sinovac Biotech Ltd. breached its 50 day moving average in a Bearish Manner : SVA-US : September 8, 2017
finance.yahoo.com - September 9 at 9:03 AM
Sinovac Biotech Ltd. breached its 50 day moving average in a Bearish Manner : SVA-US : September 8, 2017Sinovac Biotech Ltd. breached its 50 day moving average in a Bearish Manner : SVA-US : September 8, 2017
finance.yahoo.com - September 9 at 9:03 AM
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Sinovac Biotech Ltd. (SVA) & Lead Plaintiff Deadline: September 1, 2017FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Sinovac Biotech Ltd. (SVA) & Lead Plaintiff Deadline: September 1, 2017
finance.yahoo.com - September 2 at 9:11 AM
DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Sinovac Biotech Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 1, 2017 - SVADEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Sinovac Biotech Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 1, 2017 - SVA
finance.yahoo.com - September 2 at 9:11 AM
DEADLINE TOMORROW: The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Sinovac Biotech Ltd. Shareholders and a Lead Plaintiff Deadline of September 1, 2017 (SVA)DEADLINE TOMORROW: The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Sinovac Biotech Ltd. Shareholders and a Lead Plaintiff Deadline of September 1, 2017 (SVA)
finance.yahoo.com - September 1 at 9:21 AM
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Sinovac Biotech Ltd. (SVA) & Lead Plaintiff Deadline: September 1, 2017DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Sinovac Biotech Ltd. (SVA) & Lead Plaintiff Deadline: September 1, 2017
finance.yahoo.com - September 1 at 9:21 AM
DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Sinovac Biotech Ltd. and Encourages Investors with Losses to Contact the FirmDEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Sinovac Biotech Ltd. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 1 at 9:21 AM
September 1st Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sinovac Biotech Ltd.September 1st Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sinovac Biotech Ltd.
www.businesswire.com - August 31 at 10:35 AM
DEADLINE FRIDAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against Sinovac Biotech Ltd. and Reminds Investors with Losses to Contact the FirmDEADLINE FRIDAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against Sinovac Biotech Ltd. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 31 at 10:35 AM
Contrasting Fortress Biotech (FBIO) and Sinovac Biotech (SVA)Contrasting Fortress Biotech (FBIO) and Sinovac Biotech (SVA)
www.americanbankingnews.com - August 29 at 12:22 AM
ONE WEEK DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Sinovac Biotech Ltd. and Encourages Investors with Losses to Contact the FirmONE WEEK DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Sinovac Biotech Ltd. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - August 26 at 9:07 AM
SVA EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Sinovac Biotech Ltd. and a Lead Plaintiff Deadline of September 1, 2017SVA EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Sinovac Biotech Ltd. and a Lead Plaintiff Deadline of September 1, 2017
finance.yahoo.com - August 24 at 6:33 PM
DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Sinovac Biotech Ltd. (Nasdaq: SVA) To Contact The FirmDEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Sinovac Biotech Ltd. (Nasdaq: SVA) To Contact The Firm
finance.yahoo.com - August 24 at 6:33 PM
IMMINENT SINOVAC LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sinovac Biotech, Ltd. To Contact The FirmIMMINENT SINOVAC LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sinovac Biotech, Ltd. To Contact The Firm
finance.yahoo.com - August 24 at 6:33 PM

SEC Filings

Sinovac Biotech (NASDAQ:SVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sinovac Biotech (NASDAQ:SVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sinovac Biotech (NASDAQ SVA) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.